An international study🌎🙌🏻 in young women with #breastcancer and BRCA1/2 germline pathogenic variants reveals the following:
1️⃣Low-HER2 disease is less common in these patients compared with older women.
2️⃣Tumors with low HER2 are more frequently associated with PV BRCA2 than PV

The OncoAlert🚨NEWSLETTER is out! Covering May 9-16, 2024.
REGISTER👉 OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…
Topics include:

Interesting results from the IMpassion132 trial🚨 in triple-negative #breastcancer , adding atezolizumab to chemotherapy did not improve overall survival for patients with rapid recurrence and PD-L1 positive.
Key facts🔑:
🔴68% had a disease-free interval of <6 months,

Interesting results😱 from the DESTINY-Gastric01 study highlighting the potential efficacy of Trastuzumab Deruxtecan (T-DXd) in the treatment of HER2+ gastric cancer.
🎯Improvement was seen even in patients with low HER2, suggesting a potential benefit for this subgroup.

Is more is better ? IMADGIST.
6 years vs 3 years of adjuvant imatinib for high risk GIST . DFS benifit. Os immature. Will u change your practice? Or u will u reintroduce imatinib on relapse? Yakup Ergün Yüksel Ürün Dr. Iván R. González ESMO - Eur. Oncology #virtualplenary

A nonrandomized phase 2 study🤓🙌🏻 evaluated the combination of nivolumab and ipilimumab in metastatic urothelial carcinoma.
🟢Cohort 1 saw a response rate of 29% in the first line and 23% in the second/third line, with three-year overall survival of 32%.
🔵In cohort 2, the

Interesting results😱 from the RE-AKT trial, capivasertib in combination with enzalutamide for metastatic castration-resistant #prostatecancer after docetaxel and abiraterone.
🎯The main results highlight that, despite the well-tolerated combination of capivasertib and

🚨 The OncoAlert newsletter is here! Access the latest oncology breakthroughs from May 2-8, 2024, at OncoAlert360.com or oncoalert.m-pages.com/nhMpwe/oncoale….

Highlights:
✅ The Lancet Commission on #ProstateCancer ✅ DESTINY-PanTumor01 ✅ Osimertinib + treatment for brain metastases

An exciting multicenter study 🤓👉on Abemaciclib, a selective inhibitor of CDK4/6-dependent kinases, offers a safety and efficacy profile in the treatment of a variety of solid tumors, including #breastcancer and #NSCLC 🫁, among others. With a sizable sample of 225 patients

The NEOpredict-Lung study represents an importantevolution in the treatment of resectable NSCLC - Dr. Iván R. González
OncoAlert Faces of Lung Cancer LungCancerAmerica Nina Maouelainin, DO, FCCP, MBA Lara Pijuan,MD PhD Nirmal Raut
oncodaily.com/60204.html

#Cancer #Oncology Center #NSCLC #OncoDaily #Oncology

Dear Colleagues,
One Month until #ASCO24 🌐
WE ARE READY
WE ARE OncoAlert 🚨

#OncoAlertAF
Dra. María Natalia Gandur Quiroga 🇦🇷
Alizée Camps - - Maléa 🇫🇷
Marta Perachino 🇮🇹
Kathrin Heinrich 🇩🇪
Biagio Ricciuti, MD PhD 🇺🇸
Deniz Can Guven 🇹🇷
Emre Yekedüz 🇺🇸
Hidehito HORINOUCHI 🇯🇵
Fadi Haddad, MD 🇺🇸
Dr. Iván R. González 🇲🇽

Interesting results 😱🙌🏻of the MITO END-3 clinical trial highlight that immunotherapy with adjuvant Avelumab and chemotherapy significantly improves survival in patients with advanced #endometrialcancer .
🌟Response variability associated with molecular profiling was observed:

In this comprehensive review🫨👉, we highlight the role of circular RNAs in modulating resistance to #cancer #immunotherapy .🦠
🟡They examined how circRNAs can offer invaluable information about how likely a patient is to respond positively to immunotherapy, which could

📢 Latest news from April 25 to May 1, 2024 with OncoAlert! Sign up for more updates!
✅ DESTINY-Breast06: Improvements in PFS in patients with low and ultra-low HER2. ✅ Monarch E: Advances in breast cancer treatment. ✅ US Preventive S Task force:

The NEOpredict-Lung study represents an important🤓evolution in the treatment of resectable NSCLC🫁, evaluating the feasibility and safety of preoperative combined treatment of nivolumab and relatlimab. The selection of this therapeutic approach was based on the premise that

Completely agree with our OncoAlert 🚨Faculty Ben Westphalen 🇩🇪

We have been seeing the same with the emergence of new accounts that are NOT adding to the conversation but rather are the same echo chambers we have been avoiding in Oncology SoMe

OncoAlert has always been and

Excellent team!👏🎉

An Amazing DAY2⃣of #APCCC24
Grateful to Advanced Prostate Cancer Consensus Conference silke gillessen
aurelius omlin and Team🇨🇭 for the AMAZING efforts that led to this GREAT meeting in #ProstateCancer

✅2⃣1⃣MILLION Impressions
✅OVER 3⃣.3⃣K Tweets
✅OncoAlert Faculty 1⃣4⃣.5⃣ million impressions

Dra. María Natalia Gandur Quiroga

🎉 Exciting results from Dr. Richard Baum in Germany on the use of actinium-PSMA for prostate cancer! Promising advancements in treatment efficacy. #ProstateCancer #ActiniumPSMA #FMMNIM

We're exploring 🙌how to integrate nuclear medicine into radiotherapy for studies that assess responses while serving for simulation and planning. Bridging disciplines for comprehensive patient care! 🩷 #Radiology OncoReporte SOMERA Sociedad Mexicana de Radioterapeutas American Board of Radiology